1287results about "Multivalent vaccine" patented technology

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

This disclosure relates to fusion proteins comprising one or more EBV polypeptides and a ferritin protein, and their use in eliciting antibodies against EBV.

The invention provides an H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (neuraminidase) protein tandem as a target and a preparation method of the H1N1 broad-spectrum mRNA vaccine, and relates to the technical field of vaccine preparation, the amino acid sequence of the mRNA vaccine is shown as SEQ ID NO.1, and the nucleotide sequence of the mRNA vaccine is shown as SEQ ID NO.2, namely, the mRNA vaccine is obtained by connecting GGGSGGSGGGSGGGGS with conserved amino acid sequences of hemagglutinin HA and neuraminidase NA. The defects in the prior art are overcome, and the broad spectrum and the protection effect of the vaccine are improved, so that the vaccine can better cope with the immune escape of the latest variant in the future.

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.

The present invention provides engineered soluble F proteins of paramyxoviruses, such as respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and human parainfluenza virus (hPIV). These engineered proteins are stabilized by specific modifications in the wild-type soluble F sequence, such as substitutions in the 023 chain and / or the introduction of engineered disulfide bonds in the 0 hairpin in the F1 subunit. The present invention also provides a nanoparticle vaccine comprising an engineered soluble F immunogen displayed on a self-assembled nanoparticle. The invention also provides methods of using such vaccine compositions in a variety of therapeutic applications, e.g., methods for preventing or treating viral infections, such as RSV, MPV, and PIV infections.

The Human Immunodeficiency Virus (HIV) infection and recurrent infection prevention mRNA vaccine comprising epitopes of HIV-1 and HIV-2 viruses and their corresponding Nef proteins.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The invention relates to an HSV-2 three-antigen subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of biology. The vaccine comprises an HSV-2 recombinant protein and a composite adjuvant, the HSV-2 recombinant protein comprises extracellular domains of three proteins, namely, HSV-2 gB2, HSV-2 gD2 and HSV-2 gE2; the composite adjuvant is composed of CpG oligodeoxynucleotide and an aluminum adjuvant. According to the HSV-2 three-antigen subunit vaccine, gB2, gD2 and gE2 proteins of HSV-2 serve as antigens, CpG oligodeoxynucleotide and an aluminum adjuvant serve as composite adjuvants, a BALB / c mouse is immunized in an intramuscular injection mode, high-level gB2, gD2 and gE2 specific IgG antibodies are successfully induced, and the neutralizing capacity of immune serum to an HSV-2 virus strain and the cross neutralizing capacity of immune serum to an HSV-1 virus strain are effectively improved.

The Human Immunodeficiency Virus (HIV) infection and recurrent infection prevention mRNA vaccine comprising epitopes of HIV-1 and HIV-2 viruses and their corresponding Nef proteins.

To provide a method for selecting a subject for whom the effect of a pharmaceutical composition for treating or preventing cancer can be expected.SOLUTION: A step of determining an expression level of WT1mRNA using a sample collected from a subject, and a step of providing an indicator that the subject is a subject for whom the pharmaceutical composition is expected to be effective when the expression level of WT1mRNA is less than or equal to or less than 10000 copies / μ gRNA.SELECTED DRAWING: None

The invention relates to low dose compositions and peptides or peptide sequences that induce an immune response in an animal or a mammal that is protective against infection by one or more pathogens, and the antibodies generated. In addition, the invention relates to immunogenic composition and vaccines comprising compositions and peptide sequences or antibodies, and to methods for treating and preventing an infection in animals and mammals such as humans.

Disclosed are multi-peptide compositions and / or methods of use of the multi-peptide compositions for patients with resected (or definitively treated) high-risk uveal melanoma. Pharmaceutically acceptable embodiments administered to patients may raise an immune system response against uveal melanoma cells, leading to a decrease in uveal melanoma cell number. Further embodiments may take the form of an adjuvant therapy or a neoadjuvant therapy, as monotherapy or in combination with other therapies.

Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CDS T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and / or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and / or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).

The present application relates to a kind of HSV-2 three antigen tandem recombinant protein vaccine compositions and its application, belong to the field of biotechnology.The vaccine composition includes antigen and composite adjuvant, antigen is HSV-2 gC2-gD2-gE2 three antigen tandem recombinant protein, composite adjuvant is CpG oligonucleotide and aluminum adjuvant;Wherein, HSV-2 gC2-gD2-gE2 three antigen tandem recombinant protein amino acid sequence as shown in SEQ ID NO.1, nucleotide sequence as shown in SEQ ID NO.2.The present application greatly reduces the time cost and economic cost in the process of protein preparation, compared with the original trivalent combination vaccine, it can induce the specific antibody level and neutralizing virus ability of mouse generation does not occur reduction, which provides a kind of new idea for developing advanced multi-target antigen HSV-2 virus vaccine, also provides a kind of safe and effective HSV-2 virus candidate vaccine.

The present invention provides influenza viruses that exhibit enhanced growth in Vero cells. The influenza viruses include PB1, PB2, PA, NP, and NS gene segments that encode proteins having amino acid sequences that include selected amino acids. Optionally, at least one of the PB1, PB2, and PA gene segments includes a promoter cytosine to uracil mutation at nucleotide position 4. The present invention also provides pharmaceutical formulations containing the influenza viruses, methods for inducing an immune response in a mammal by administering the influenza viruses to a mammal, and methods for producing influenza viruses.

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express one or more cancer antigen comprising PD-L1 and / or IDO1. Also provided herein are methods for treating a cancer.

The invention relates to RNA constructs encoding (i) at least one therapeutic biomolecule; and (ii) at least one innate inhibitor protein (IIP). The constructs are RNA replicons and saRNA molecules, and the invention includes genetic constructs or vectors encoding such RNA replicons. The invention extends to the use of such RNA constructs and replicons in therapy, for example in treating diseases and / or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.

Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express a cancer antigen comprising PD-L1. Also provided herein are methods for treating a cancer.

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

This invention relates to compositions (e.g. immunogenic compositions) which can be used to immunise against C. acnes. The compositions comprise C. acnes antigens and antigen combinations, used in the form of nucleic acids (e.g. mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

The present invention pertains to the use of a vaccine based on an alphavirus RNA replicon particle (αRP) vector encoding an antigen of an IAV-S for the passive vaccination of piglets against a pathogenic infection with swine influenza virus.

The present invention relates to compositions (e.g., vaccine compositions) useful for immunizing against Chlamydia infection. These compositions comprise Chlamydia species antigens and antigen combinations that can be used to immunize against Chlamydia species, which antigens and antigen combinations are used in the form of nucleic acids (e.g., mRNA) encoding antigen proteins or in the form of recombinant protein antigens.

The invention relates to molecular glue for forming fimbriae related protein based on SpaA isopeptide bonds of Vinci bacteria. The invention also relates to a nanoparticle vaccine composition formed by the molecular glue, and the immunogen is covalently displayed on the surface of the nanoparticle by the molecular glue.

The invention relates to a novel HSV-2 three-antigen recombinant protein vaccine composition and application thereof, and belongs to the technical field of biology. The vaccine composition comprises an antigen and a composite adjuvant, the antigen is HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the amino acid sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 1, and the nucleotide sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 2. The time cost and the economic cost in the protein preparation process are greatly reduced, and compared with an original trivalent combination vaccine, the trivalent combination vaccine can induce the level of specific antibodies generated by mice and the virus neutralizing capacity not to be reduced, so that a brand new thought is provided for developing advanced HSV-2 virus vaccines with multiple target antigens, and the trivalent combination vaccine is worthy of popularization and application. Meanwhile, the invention also provides a safe and effective HSV-2 virus candidate vaccine.

The invention provides a subunit vaccine composition for porcine epidemic diarrhea, porcine delta coronal and porcine rotavirus as well as a preparation method and application of the subunit vaccine composition, and is characterized in that the subunit vaccine composition comprises prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein, viral subunit protein and pharmaceutically acceptable adjuvants; wherein the amino acid sequence of the prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein is as shown in SEQ No.1, and the viral subunit protein is selected from one or more of porcine epidemic diarrhea virus S protein, porcine delta coronavirus S protein and porcine rotavirus VP8 protein. The vaccine composition disclosed by the invention has the advantages of strong immunogenicity, good safety, no immune interference, high neutralizing antibody titer and long antibody duration.

To provide optimized cancer vaccines, as well as methods of making the vaccines, methods of using the vaccines, and compositions comprising the vaccines, and further provide a computerized system for selecting nucleic acids to be incorporated into an optimized cancer vaccine.SOLUTION: The present invention provides a nucleic acid cancer vaccine, comprising one or more nucleic acids each having one or more open reading frames encoding 5 to 130 peptide epitopes, wherein each of the peptide epitopes are portions of personalized cancer antigens, wherein at least two of the peptide epitopes have different lengths.SELECTED DRAWING: None